中图分类号：R692 文献标识码：A文章编号：1006-1959(2025)14-0119-04

    DOI：10.3969/j.issn.1006-1959.2025.14.023

    Abstract：ObjectieTivestgateheectofsacubitrlalsartanombindwitemodialysisoniflammatorateandonemeabolismin patientswithchonickidneydiseaseMethodsAtotalof6patientsithchoickidneydiseasediagosedndtreatedinShangraoGuangin DistrictPeoplesspitalfoJuarytoOctoereeseleedsteseachjectsodngtoeadumbeableethod theyweredividedintoooloddoith3Oatitsiachopotroastreatedimodalisd groupwastraedwicbitillsaraosisoftolouprapetevelfatorctorseacti protein(RP)，atiUabloda phosphatase(BALP)werecomparedbetweenthetwogroups.ResultsThetotalefectiverateoftreatmentinthestudygroup 96.67% )washigher than that in the control group (73.33 % )( Plt; 0.05).Compared with thecontrol group，thelevelsofCRP，Scr，BUN，BALPand serumphosphorus inthe study group were lower after treatment，while the level of serum calcium was higher( P lt;0.05).Conclusion Sacubitril valsartan combined with hemodialysissfiteetinpatitsiocdeydseaseichpoethifaatoyatedeetabolcactoee of patients，and improve their renal function of patients.It is worthy of clinical application. ......